Estimation of the dissociation constants for pulmonary endothelial angiotensin converting enzyme reactions with trandolaprilat and enalaprilat in vivo

Stylianos E. Orfanos, James Parkerson, Lyle E Fisher, John D. Catravas

Research output: Contribution to journalArticle

Abstract

We estimated the activity of pulmonary capillary endothelium-bound (PCEB) angiotensin converting enzyme (ACE) in the rabbit in vivo, before and at 20 min and 2 h postadministration of the ACE inhibitors trandolaprilat (8 μg/kg) and enalaprilat (10 μg/kg), alone and in combination with the calcium channel blocker verapamil (100 μg/kg). PCEB ACE activity was assessed from the single-pass transpulmonary hydrolysis of the synthetic substrate 3H-benzoyl-Phe-Ala-Pro (BPAP). We then calculated the modified kinetic parameter A(max)/K(m) and the dissociation constants (k-1) of the two inhibitors from PCEB ACE. Trandolaprilat reduced PCEB ACE activity less than enalaprilat, but its action was more sustained. Verapamil did not influence the immediate inhibitory action of either inhibitor. Enalaprilat exhibited more than a threefold higher k-1 than trandolaprilat from PCEB ACE (77.9 ± 9.2 vs. 25.2 ± 4.3 x 10-5/sec). Co-injection of verapamil did not significantly affect the k-1 of enalaprilat (86.3 ± 5.2 x 10-5/sec) but moderately increased that of trandolaprilat (45.2 ± 6 x 10-5/sec). We conclude that 1) trandolaprilat confers a longer-lasting enzyme inhibition than enalaprilat, and 2) although the trandolaprilat-verapamil treatment moderately reduces the duration of the trandolaprilat-induced inhibition, it still offers a longer enzyme inhibition than enalaprilat alone or in combination with verapamil.

Original languageEnglish (US)
Pages (from-to)80-86
Number of pages7
JournalDrug Development Research
Volume44
Issue number2-3
DOIs
StatePublished - Jun 1 1998

Fingerprint

Enalaprilat
Peptidyl-Dipeptidase A
Vascular Endothelium
Verapamil
Lung
Calcium Channel Blockers
Enzymes
trandolaprilat
Angiotensin-Converting Enzyme Inhibitors
Hydrolysis
Rabbits
Injections

Keywords

  • Angiotensin converting enzyme
  • Dissociation constant
  • Enalaprilat
  • Hypertension
  • Pulmonary capillary endothelium
  • Trandolaprilat

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Estimation of the dissociation constants for pulmonary endothelial angiotensin converting enzyme reactions with trandolaprilat and enalaprilat in vivo. / Orfanos, Stylianos E.; Parkerson, James; Fisher, Lyle E; Catravas, John D.

In: Drug Development Research, Vol. 44, No. 2-3, 01.06.1998, p. 80-86.

Research output: Contribution to journalArticle

@article{be459f05c44848798ebad51599419c39,
title = "Estimation of the dissociation constants for pulmonary endothelial angiotensin converting enzyme reactions with trandolaprilat and enalaprilat in vivo",
abstract = "We estimated the activity of pulmonary capillary endothelium-bound (PCEB) angiotensin converting enzyme (ACE) in the rabbit in vivo, before and at 20 min and 2 h postadministration of the ACE inhibitors trandolaprilat (8 μg/kg) and enalaprilat (10 μg/kg), alone and in combination with the calcium channel blocker verapamil (100 μg/kg). PCEB ACE activity was assessed from the single-pass transpulmonary hydrolysis of the synthetic substrate 3H-benzoyl-Phe-Ala-Pro (BPAP). We then calculated the modified kinetic parameter A(max)/K(m) and the dissociation constants (k-1) of the two inhibitors from PCEB ACE. Trandolaprilat reduced PCEB ACE activity less than enalaprilat, but its action was more sustained. Verapamil did not influence the immediate inhibitory action of either inhibitor. Enalaprilat exhibited more than a threefold higher k-1 than trandolaprilat from PCEB ACE (77.9 ± 9.2 vs. 25.2 ± 4.3 x 10-5/sec). Co-injection of verapamil did not significantly affect the k-1 of enalaprilat (86.3 ± 5.2 x 10-5/sec) but moderately increased that of trandolaprilat (45.2 ± 6 x 10-5/sec). We conclude that 1) trandolaprilat confers a longer-lasting enzyme inhibition than enalaprilat, and 2) although the trandolaprilat-verapamil treatment moderately reduces the duration of the trandolaprilat-induced inhibition, it still offers a longer enzyme inhibition than enalaprilat alone or in combination with verapamil.",
keywords = "Angiotensin converting enzyme, Dissociation constant, Enalaprilat, Hypertension, Pulmonary capillary endothelium, Trandolaprilat",
author = "Orfanos, {Stylianos E.} and James Parkerson and Fisher, {Lyle E} and Catravas, {John D.}",
year = "1998",
month = "6",
day = "1",
doi = "10.1002/(SICI)1098-2299(199806/07)44:2/3<80::AID-DDR5>3.0.CO;2-6",
language = "English (US)",
volume = "44",
pages = "80--86",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "2-3",

}

TY - JOUR

T1 - Estimation of the dissociation constants for pulmonary endothelial angiotensin converting enzyme reactions with trandolaprilat and enalaprilat in vivo

AU - Orfanos, Stylianos E.

AU - Parkerson, James

AU - Fisher, Lyle E

AU - Catravas, John D.

PY - 1998/6/1

Y1 - 1998/6/1

N2 - We estimated the activity of pulmonary capillary endothelium-bound (PCEB) angiotensin converting enzyme (ACE) in the rabbit in vivo, before and at 20 min and 2 h postadministration of the ACE inhibitors trandolaprilat (8 μg/kg) and enalaprilat (10 μg/kg), alone and in combination with the calcium channel blocker verapamil (100 μg/kg). PCEB ACE activity was assessed from the single-pass transpulmonary hydrolysis of the synthetic substrate 3H-benzoyl-Phe-Ala-Pro (BPAP). We then calculated the modified kinetic parameter A(max)/K(m) and the dissociation constants (k-1) of the two inhibitors from PCEB ACE. Trandolaprilat reduced PCEB ACE activity less than enalaprilat, but its action was more sustained. Verapamil did not influence the immediate inhibitory action of either inhibitor. Enalaprilat exhibited more than a threefold higher k-1 than trandolaprilat from PCEB ACE (77.9 ± 9.2 vs. 25.2 ± 4.3 x 10-5/sec). Co-injection of verapamil did not significantly affect the k-1 of enalaprilat (86.3 ± 5.2 x 10-5/sec) but moderately increased that of trandolaprilat (45.2 ± 6 x 10-5/sec). We conclude that 1) trandolaprilat confers a longer-lasting enzyme inhibition than enalaprilat, and 2) although the trandolaprilat-verapamil treatment moderately reduces the duration of the trandolaprilat-induced inhibition, it still offers a longer enzyme inhibition than enalaprilat alone or in combination with verapamil.

AB - We estimated the activity of pulmonary capillary endothelium-bound (PCEB) angiotensin converting enzyme (ACE) in the rabbit in vivo, before and at 20 min and 2 h postadministration of the ACE inhibitors trandolaprilat (8 μg/kg) and enalaprilat (10 μg/kg), alone and in combination with the calcium channel blocker verapamil (100 μg/kg). PCEB ACE activity was assessed from the single-pass transpulmonary hydrolysis of the synthetic substrate 3H-benzoyl-Phe-Ala-Pro (BPAP). We then calculated the modified kinetic parameter A(max)/K(m) and the dissociation constants (k-1) of the two inhibitors from PCEB ACE. Trandolaprilat reduced PCEB ACE activity less than enalaprilat, but its action was more sustained. Verapamil did not influence the immediate inhibitory action of either inhibitor. Enalaprilat exhibited more than a threefold higher k-1 than trandolaprilat from PCEB ACE (77.9 ± 9.2 vs. 25.2 ± 4.3 x 10-5/sec). Co-injection of verapamil did not significantly affect the k-1 of enalaprilat (86.3 ± 5.2 x 10-5/sec) but moderately increased that of trandolaprilat (45.2 ± 6 x 10-5/sec). We conclude that 1) trandolaprilat confers a longer-lasting enzyme inhibition than enalaprilat, and 2) although the trandolaprilat-verapamil treatment moderately reduces the duration of the trandolaprilat-induced inhibition, it still offers a longer enzyme inhibition than enalaprilat alone or in combination with verapamil.

KW - Angiotensin converting enzyme

KW - Dissociation constant

KW - Enalaprilat

KW - Hypertension

KW - Pulmonary capillary endothelium

KW - Trandolaprilat

UR - http://www.scopus.com/inward/record.url?scp=0031662812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031662812&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2299(199806/07)44:2/3<80::AID-DDR5>3.0.CO;2-6

DO - 10.1002/(SICI)1098-2299(199806/07)44:2/3<80::AID-DDR5>3.0.CO;2-6

M3 - Article

AN - SCOPUS:0031662812

VL - 44

SP - 80

EP - 86

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 2-3

ER -